Skip to main content

Evotec Inks Deal with Apeiron to Use Chemical Proteomics in Cancer Drug Development

Premium

German pharmaceutical firm Evotec said this week that it has entered a research collaboration with Apeiron Biologics in which it will apply its chemical proteomic capabilities to the development of immunomodulatory compounds to treat cancer.

The agreement stems from a successful high-throughput phenotypic screen previously performed for Apeiron by Evotec, the company said in a statement.

Evotec obtained its chemical proteomics assets through its 2011 purchase of proteomics firm Kinaxo Biotechnologies for €16 million ($22 million). Kinaxo, which was spun out of the Max Planck Institute by researchers including Matthias Mann, used mass-spec-based competition binding assays to profile small molecule drugs and drug targets.

In June 2011, Evotec signed a deal with Roche to use the technology to identify biomarkers for oncology drugs in Roche's pipeline (PM 7/1/2011). Prior to the acquisition, Kinaxo had collaborations ongoing with pharma firms including Takeda and AstraZeneca.

Apeiron is a Vienna-based biotech firm with five current clinical programs, including projects developing therapies for neuroblastoma and inflammation.

Financial and other details of the agreement were not provided.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.